


List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12087440/publications.pdf Version: 2024-02-01



SDVVAS

#	Article	IF	CITATIONS
1	Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. International Journal of Pharmaceutics, 2001, 228, 43-52.	2.6	235
2	Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. International Journal of Pharmaceutics, 2004, 269, 37-49.	2.6	230
3	Nanocarriers in Ocular Drug Delivery: An Update Review. Current Pharmaceutical Design, 2009, 15, 2724-2750.	0.9	157
4	Mannosylated niosomes as adjuvant–carrier system for oral genetic immunization against Hepatitis B. Immunology Letters, 2005, 101, 41-49.	1.1	143
5	Non-ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. International Journal of Pharmaceutics, 2005, 296, 80-86.	2.6	134
6	Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. Journal of Drug Targeting, 2010, 18, 292-302.	2.1	115
7	Controlled and targeted drug delivery strategies towards intraperiodontal pocket diseases. Journal of Clinical Pharmacy and Therapeutics, 2000, 25, 21-42.	0.7	88
8	Preparation and characterization of niosomes containing rifampicin for lung targeting. Journal of Microencapsulation, 1995, 12, 401-407.	1.2	82
9	Cationic transfersomes based topical genetic vaccine against hepatitis B. International Journal of Pharmaceutics, 2007, 340, 13-19.	2.6	74
10	Polysaccharide coated liposomes for oral immunization — development and characterization. International Journal of Pharmaceutics, 2000, 203, 169-177.	2.6	73
11	Endogenous carriers and ligands in non-immunogenic site-specific drug delivery. Advanced Drug Delivery Reviews, 2000, 43, 101-164.	6.6	71
12	Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in-vitro and in-vivo characterization. Journal of Pharmacy and Pharmacology, 2010, 58, 303-310.	1.2	70
13	Mannosylated Niosomes as Adjuvant-Carrier System for Oral Mucosal Immunization. Journal of Liposome Research, 2006, 16, 331-345.	1.5	64
14	Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis. Artificial Cells, Nanomedicine and Biotechnology, 2015, 43, 33-39.	1.9	64
15	Tailored polymer–lipid hybrid nanoparticles for the delivery of drug conjugate: Dual strategy for brain targeting. Colloids and Surfaces B: Biointerfaces, 2015, 126, 414-425.	2.5	62
16	Ligand directed macrophage targeting of amphotericin B loaded liposomes. International Journal of Pharmaceutics, 2000, 210, 1-14.	2.6	57
17	Chitosan and its Role in Ocular Therapeutics. Mini-Reviews in Medicinal Chemistry, 2009, 9, 1639-1647.	1.1	56
18	Discoidal niosome based controlled ocular delivery of timolol maleate. Die Pharmazie, 1998, 53, 466-9.	0.3	56

S P Vyas

#	Article	IF	CITATIONS
19	A Novel Cancer Targeting Approach Based on Estrone Anchored Stealth Liposome for Site-Specific Breast Cancer Therapy. Current Cancer Drug Targets, 2010, 10, 343-353.	0.8	55
20	Biofilm consortia on biomedical and biological surfaces: delivery and targeting strategies. Pharmaceutical Research, 2001, 18, 1247-1254.	1.7	47
21	Targeted delivery of doxorubicin via estrone-appended liposomes. Journal of Drug Targeting, 2008, 16, 455-463.	2.1	44
22	Topical liposomal system for localized and controlled drug delivery. Journal of Dermatological Science, 1996, 13, 107-111.	1.0	41
23	Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system(s) administered intranasally. Vaccine, 2011, 29, 4953-4962.	1.7	41
24	Proliposomes of indomethacin for oral administration. Journal of Microencapsulation, 1991, 8, 1-7.	1.2	39
25	Liposomally encapsulated diclofenac for sonophoresis induced systemic delivery. Journal of Microencapsulation, 1995, 12, 149-154.	1.2	35
26	Mannosylated niosomes as carrier adjuvant system for topical immunization. Journal of Pharmacy and Pharmacology, 2010, 57, 1177-1184.	1.2	33
27	Mannosylated liposomes for bio-film targeting. International Journal of Pharmaceutics, 2007, 330, 6-13.	2.6	32
28	Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery. Current Medicinal Chemistry, 2007, 14, 2095-2109.	1.2	31
29	Implication of Gut Immunology in the Design of Oral Vaccines. Current Molecular Medicine, 2010, 10, 47-70.	0.6	27
30	Effervescent granule based proliposomes of ibuprofen. Journal of Microencapsulation, 1990, 7, 455-462.	1.2	25
31	Preparation, characterization and in vitro antimicrobial activity of metronidazole bearing lectinized liposomes for intra-periodontal pocket delivery. Die Pharmazie, 2001, 56, 554-60.	0.3	23
32	C-Type lectin receptor(s)-targeted nanoliposomes: an intelligent approach for effective cancer immunotherapy. Nanomedicine, 2017, 12, 1945-1959.	1.7	18
33	Enhanced <i>in vivo</i> performance of liposomal indomethacin derived from effervescent granule based proliposomes. Journal of Microencapsulation, 1995, 12, 487-493.	1.2	15
34	Development and Characterization of Biocompatible Mannose Functionalized Mesospheres: an Effective Chemotherapeutic Approach for Lung Cancer Targeting. AAPS PharmSciTech, 2020, 21, 190.	1.5	15
35	Poly(phthaloyl-l-lysine)-coated multilamellar vesicles for controlled drug delivery: in vitro and in vivo performance evaluation. Pharmaceutica Acta Helvetiae, 1999, 74, 51-58.	1.2	14
36	Pressurized Pack-Based Liposomes for Pulmonary Targeting of Isoprenaline—Development and Characterization. Journal of Microencapsulation, 1994, 11, 373-380.	1.2	12

S P Vyas

#	Article	IF	CITATIONS
37	Prolonged release of rifampicin from multiple W/O/W emulsion systems. Journal of Microencapsulation, 1995, 12, 409-415.	1.2	12
38	Passive Vectoring of a Colloidal Carrier System for Sodium Stibogluconate: Preparation, Characterization and Performance Evaluation. Journal of Drug Targeting, 1993, 1, 197-206.	2.1	11
39	Localized rifampicin albumin microspheres. Journal of Microencapsulation, 1991, 8, 87-93.	1.2	10
40	Prolonged Release Multiple Emulsion Based System Bearing Rifampicin: In Vitro Characterisation. Drug Development and Industrial Pharmacy, 1995, 21, 869-878.	0.9	8
41	Multiple emulsion based systems for prolonged delivery of rifampicin: in vitro and in vivo characterization. Die Pharmazie, 1997, 52, 224-6.	0.3	8
42	Self-assessing supramolecular biovectors: a new dimension in novel drug delivery systems. Die Pharmazie, 1997, 52, 259-67.	0.3	7
43	Mannose functionalized plain and endosomolytic nanocomposite(s)-based approach for the induction of effective antitumor immune response in C57BL/6 mice melanoma model. Drug Development and Industrial Pharmacy, 2019, 45, 1089-1100.	0.9	5
44	Development and Characterisation of Supramolecular Autovectoring System for Selective Drug Delivery. Journal of Drug Targeting, 1999, 6, 315-322.	2.1	4